[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.167.142.229. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
December 7, 2011

Androgen Deprivation Therapy and Competing Risks

Author Affiliations

Author Affiliations: Departments of Medical Oncology (Dr Kelly) and Urology (Drs Kelly and Gomella), Thomas Jefferson University, Kimmel Cancer Center, Philadelphia, Pennsylvania.

JAMA. 2011;306(21):2382-2383. doi:10.1001/jama.2011.1791

Androgen deprivation therapy (ADT) has been the mainstay for the treatment of advanced prostate cancer for the past 7 decades. Surgical castration (orchiectomy) and the use of estrogens have been largely replaced by the administration of gonadotropin-releasing hormone (GnRH) agonists as the most common form of ADT used today.1,2 GnRH agonists are relatively easy to administer, avoid the well-known cardiovascular risks of estrogens and the psychological trauma of surgical castration, and allow the potential for the androgen blockade to be reversed.1,2

First Page Preview View Large
First page PDF preview
First page PDF preview
×